Hybrid Capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening.
High- and intermediate-risk types of human papillomavirus (HPV) in concert with cofactors are responsible for over 90% of cervical cancers world-wide. While the Pap smear is a valuable cancer prevention tool, its subjective nature leaves it error prone. As a result, HPV DNA testing appears to be a needed adjunct to the Pap smear. Hybrid Capture is a simple DNA test with high specificity and sensitivity which appears useful for clinical management of equivocal Pap tests and shows promise for mass screening.
Lörincz
A T
AT
Digene Corporation, Silver Spring, MD 20904, USA.
D004279:DNA, Viral / Q000032:analysis*; D005260:Female; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D008403:Mass Screening / Q000379:methods; D009693:Nucleic Acid Hybridization; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000302:isolation & purification*; D016133:Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D014412:Tumor Virus Infections / Q000473:pathology*; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000517:prevention & control / Q000821:virology*; D014626:Vaginal Smears
D004279:DNA, Viral